Evolus (EOLS) AI Stock Analysis

• Market Cap: $465.41M
• Dividend Yield: N/A
• Average Volume (3M): 1.27M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: 15.10%
• EPS Growth: 0.18%
• Country: US
• Employees: 372
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.13
• Shares Outstanding: 64,819,786
• 10 Day Avg. Volume: 2,021,848
• 30 Day Avg. Volume: 1,269,617
• PEG Ratio: 0.54
• Price to Book (P/B): 123.99
• Price to Sales (P/S): 2.57
• P/FCF Ratio: -35.16
• Enterprise Value/Market Cap: 1.09
• Enterprise Value/Revenue: 1.78
• Enterprise Value/Gross Profit: 2.70
• Enterprise Value/Ebitda: -12.00
• 1Y Price Target: $19.50
• Price Target Upside: 197.26% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -0.47
• Revenue Forecast (FY): $296.02M

• Rating: 46 Neutral
• Price Target: $7.00 ▲(6.71% Upside)

Evolus faces significant financial challenges with high leverage and negative equity, impacting its overall score. While there are positive signs from recent product launches and international expansion, the company's valuation remains unattractive due to ongoing losses. Technical indicators suggest mixed momentum, with short-term bullishness but longer-term bearish trends. The earnings call provides some optimism for future profitability, but current market conditions remain challenging.

Positive Factors

Successful Product Launch

The successful launch of Evolysse indicates strong market acceptance and potential for future revenue growth, enhancing Evolus' product portfolio.

International Expansion

International expansion into nine markets strengthens Evolus' market position and diversifies revenue streams, supporting long-term growth.

New CFO Appointment

The appointment of an experienced CFO can enhance financial management and strategic execution, crucial for navigating financial challenges and growth.

Negative Factors

Financial Instability

Ongoing financial instability with negative equity and profitability challenges could hinder Evolus' ability to invest in growth and innovation.

Negative Cash Flow

Persistent negative cash flow indicates reliance on external financing, which may limit financial flexibility and increase risk during economic downturns.

Decreased Toxin Demand

Decreased demand for Jeuveau reflects market challenges and could impact revenue growth, necessitating strategic adjustments to maintain competitiveness.

Evolus Business Overview & Revenue Model

Company Description

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

How the Company Makes Money

Evolus generates revenue primarily through the sale of its aesthetic products, with Jeuveau being its main source of income. The company employs a business model that includes direct sales to licensed healthcare professionals and partnerships with aesthetic clinics. Revenue is driven by product sales and the establishment of distribution agreements with various medical aesthetic providers. Additionally, Evolus invests in marketing and promotional campaigns to raise awareness of its products among consumers and practitioners, further enhancing its sales potential. The company's focus on innovation and the expansion of its product portfolio plays a significant role in driving revenue growth and sustaining its competitive edge in the market.

Evolus Financial Statement Overview

Summary

Evolus is experiencing revenue growth, but profitability and financial stability remain significant challenges. The high leverage and negative equity pose risks, while cash flow improvements offer a glimmer of hope. Overall, the company needs to address its cost structure and financial leverage to improve its financial health.

Income Statement

Evolus has shown some revenue growth with a TTM increase of 2.84%, but profitability remains a challenge. The company has a negative net profit margin of -22.34% and an EBIT margin of -15.60%, indicating ongoing operational losses. Despite a decent gross profit margin of 66.73%, the negative margins highlight significant cost management issues.

Balance Sheet

The balance sheet reveals a concerning financial structure with a negative stockholders' equity and a high debt-to-equity ratio of -8.31 in TTM, indicating high leverage and financial instability. Although the return on equity is positive at 17.91%, it is primarily due to the negative equity, which is a risk factor.

Cash Flow

Cash flow analysis shows a significant improvement in free cash flow growth at 85.26% TTM, yet the company still faces negative operating cash flow. The free cash flow to net income ratio is slightly above 1, suggesting some efficiency in cash management despite ongoing losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	285.38M	266.27M	202.09M	148.62M	99.67M	56.54M
Gross Profit	188.16M	182.30M	140.53M	92.73M	56.14M	38.24M
EBITDA	-42.39M	-25.00M	-41.81M	-60.72M	-39.06M	-144.75M
Net Income	-58.56M	-50.42M	-61.69M	-74.41M	-46.81M	-163.01M
Balance Sheet
Total Assets	219.00M	232.57M	189.00M	177.98M	257.48M	209.07M
Cash, Cash Equivalents and Short-Term Investments	43.52M	86.95M	62.84M	53.92M	146.26M	107.56M
Total Debt	180.77M	129.98M	126.55M	73.20M	74.74M	138.32M
Total Liabilities	247.76M	227.05M	209.69M	159.48M	175.61M	282.03M
Stockholders Equity	-28.76M	5.52M	-20.69M	18.50M	-422.88M	-376.07M
Cash Flow
Free Cash Flow	-79.09M	-19.47M	-35.63M	-11.71M	-34.36M	-61.01M
Operating Cash Flow	-75.08M	-18.00M	-34.01M	-8.77M	-33.39M	-57.87M
Investing Cash Flow	-9.91M	-4.82M	-1.63M	-1.39M	4.03M	12.19M
Financing Cash Flow	36.61M	47.41M	44.64M	-1.52M	73.05M	38.35M

Evolus Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EOLS, the sentiment is Negative. The current price of 6.56 is below the 20-day moving average (MA) of 6.66, below the 50-day MA of 6.67, and below the 200-day MA of 9.72, indicating a bearish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 48.13 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EOLS.

Evolus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EBS	71 Outperform	$539.38M	7.85	13.92%	―	-29.91%	―
DERM	60 Neutral	$232.58M	―	-57.22%	―	-27.40%	-475.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORGO	51 Neutral	$503.63M	―	-2.64%	―	-4.21%	7.78%
RMTI	47 Neutral	$35.81M	―	-8.65%	―	-6.79%	61.56%
EOLS	46 Neutral	$465.41M	―	―	―	15.10%	0.18%
AQST	45 Neutral	$725.84M	―	―	―	-26.32%	-56.54%

Evolus Corporate Events

Evolus, Inc. Reports Strong Q3 2025 Growth

Evolus, Inc. is a global performance beauty company specializing in aesthetic injectables, with a focus on consumer-centric products and innovative digital platforms. The company is known for its flagship products, Jeuveau® and Evolysse™, which are designed to redefine the aesthetic injectable market.

Evolus Appoints Tatjana Mitchell as New CFO

On September 8, 2025, Evolus, Inc. announced the appointment of Tatjana Mitchell as its new Chief Financial Officer. With over 20 years of experience in strategic and operational finance, Mitchell is expected to play a crucial role in driving revenue growth and operational excellence as Evolus expands its portfolio and global footprint. Her previous roles include Senior Vice President of Corporate Finance at Experian and CFO at Zulily, where she demonstrated a strong track record in financial management and strategic execution.

The most recent analyst rating on (EOLS) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Evolus stock, see the EOLS Stock Forecast page.

Evolus, Inc. Advances Safety Study of NUCEIVA for Glabellar Lines

Evolus, Inc. is conducting a non-interventional post-authorization safety study (PASS) titled ‘Non-Interventional Post-Authorisation Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines.’ The study aims to further characterize the long-term safety of NUCEIVA, a treatment for glabellar lines, in real-world clinical settings. This research is significant as it provides insights into the safety profile of NUCEIVA, which is crucial for its continued use and acceptance in the market.

Evolus, Inc. Faces Financial Instability Amid Economic Uncertainty and Consumer Spending Risks

Evolus, Inc. faces significant business risks due to its reliance on consumer discretionary spending and the unpredictable nature of global economic conditions. The company’s products are not reimbursed by government or third-party payors, making them dependent on direct consumer payments, which are influenced by economic factors such as tariffs and inflation. The lack of long-term purchase commitments with customers further exacerbates this volatility, as purchasing decisions are influenced by trends, competitor tactics, and economic conditions affecting liquidity. Recent macroeconomic challenges, including inflationary pressures and tariffs, have already impacted consumer sentiment and procedural volumes, posing a threat to Evolus, Inc.’s financial stability if these conditions persist.

Evolus, Inc. Earnings Call: Mixed Sentiments and Strategic Goals

Evolus, Inc. recently held its earnings call, revealing a mixed sentiment among stakeholders. The company celebrated significant achievements, such as the successful launch of Evolysse and strides in international expansion. However, these positives were tempered by challenges in the U.S. toxin market and a revised financial outlook due to prevailing economic headwinds.